Phase 2 topline — cemiplimab
Regeneron Pharmaceuticals, Inc. · NASDAQ · $70.5B market cap
Q4 2026
Bias Score
P(positive outcome)
Forecast move
Date confidence
45%
Company guidance for a period, e.g. 2H 2026.
What this event is
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
- Drug
- cemiplimab
- Mechanism
- —
- Indication
- Melanoma
- Primary endpoint
- Pathological complete response (pCR) rate as assessed by Blinded Independent Pathological Review (BIPR)
- Enrollment
- 151
- Source
- ClinicalTrials.gov
Full dossier
Trial design and what the registration does and does not record, the primary endpoint and how it is assessed, where the date comes from and how firm it is, and the balance-sheet position going into the print.
Aperture unlocks the full dossier on every event — trial design, endpoint, date provenance, balance sheet.
See pricingHow the model got here
Aperture unlocks the model's written rationale for each score.
See pricingFeature attribution
Aperture unlocks per-event feature attribution from the model.
See pricingTwo-sided forecast
Aperture unlocks the calibrated probability and Bias Score for every event.
See pricingCompany
- Market cap
- $70.5B
- Cash
- $8.0B
- Runway
- —
- Approved products
- 0
Research, not advice. Aperture is not a registered investment adviser or broker-dealer and does not provide personalised recommendations. Nothing here is sized to your circumstances. Trial details come from the sponsor's own ClinicalTrials.gov registration, which sponsors revise; the date is the registered primary completion date, not a commitment.